Monte Rosa Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other information
Rule 10b5-1 Trading Plans
During the fiscal quarter ended on June 30, 2026, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted, modified orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408(a) of Regulation S-K, except as described in the table below.
| Name and Title | Action | Action Date | Duration of Trading Arrangements | Rule 10b5-1 Trading Arrangement? (Y/N)* | Aggregate Number of Securities Subject to Trading Arrangement |
|---|---|---|---|---|---|
| Kimberly BlackwellDirector | Adopt | April 15, 2026 | August 11, 2026- April 23, 2027 | Y | Up to 35,500 shares of common stock underlying stock options to be sold |
| Markus WarmuthChief Executive Officer | Adopt | June 18, 2026 | January 7, 2027 - August 13, 2027 | Y | Up to 54,500 shares of common stock underlying restricted stock units |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.